|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
To analyze the efficacy and tolerability of cabozantinib-a small molecule inhibitor of MET and VEGFR2-alone or with trastuzumab in patients with breast cancer brain metastases (BCBM).
|
31541381 |
2020 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Our previous study showed that MET inhibition by pan-kinase inhibitors has synergism with PARPi in suppressing growth of breast cancer <i>in vitro</i> and in xenograft tumor models.
|
30949414 |
2019 |
|
Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Accordingly, cross-species analysis revealed gene-level murine CNAs were present in a subset of human breast cancers with high MET and YAP1 mRNA predictive of decreased relapse-free survival in basal-like breast cancers.
|
30597648 |
2019 |
|
Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Hepatocyte growth factor receptor (c-MET) is a receptor tyrosine kinase overexpressed in malignant cancer types, including breast cancer.
|
30962283 |
2019 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
In addition, MET is a directly targeted gene of miR-182 in breast cancer cells.
|
29925897 |
2019 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
The novel epigenetic mechanism of FEN1 on proliferation promotion provides a significant clue that FEN1 might serve as a predictive biomarker and therapeutic target for breast cancer.-Zeng, X., Qu, X., Zhao, C., Xu, L., Hou, K., Liu, Y., Zhang, N., Feng, J., Shi, S., Zhang, L., Xiao, J., Guo, Z., Teng, Y., Che, X. FEN1 mediates miR-200a methylation and promotes breast cancer cell growth <i>via</i> MET and EGFR signaling.
|
31266372 |
2019 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Besides providing the first identification and detailed description of L1-MET in breast cancer, we clearly demonstrate that higher levels of this transcript specifically recognize a subset of more aggressive carcinomas, mainly TNBC.
|
30144023 |
2018 |
|
Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Flow cytometric analysis of luminal and basal-like breast cancer cell lines and examination of 801 tumor specimens from a prospective cohort of breast cancer patients using reverse phase protein arrays revealed that expression of TGFBR2 and MET is increased in basal-like breast cancer cell lines, as well as in triple-negative breast cancer tumor tissues, compared to other subtypes.
|
30004628 |
2018 |
|
Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
RESULTS Expression of c-Met protein was increased in breast cancer tissue compared with normal breast tissue.
|
30444219 |
2018 |
|
Malignant neoplasm of breast
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
HER2 amplified GOC differs from breast cancer due to inherent differences in the HER2 amino-truncation and mutation rate, loss of HER2 expression, alterations in HER2 signalling pathways and differences in insulin-like growth factor-1 receptor and MET expression.
|
30079142 |
2018 |
|
Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Dysregulations of MET expression and/or signaling have been reported and determined to be associated with inferior outcomes in breast cancer patients rendering MET a versatile candidate for targeted therapeutic intervention.
|
29042798 |
2017 |
|
Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
Human basal-like breast cancers with predicted mutated p53 status had higher levels of MET expression than tumors with wild-type p53.
|
27775073 |
2017 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Our meta-analysis showed that CXCR4 and C-Met were efficient prognostic factors for breast cancer.
|
27214240 |
2016 |
|
Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
An immunogenotypic signature of low complexity comprising MET relative copy number and Ki-67 expression generated by dual ISH and IHC may help predict pCR in ERBB2-positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab.
|
27576528 |
2016 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Our data demonstrate for the first time a role for pre-OBs in mediating HGF/MET- dependent migration of BC cells and strongly support the clinical evaluation of INCB28060 and other MET inhibitors to limit and/or prevent BC-associated bone metastases.
|
26934743 |
2016 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Age-adjusted and multivariable Cox regression models were performed to determine the relationship between exercise exposure (total MET-hours/week) and recurrence and breast cancer-related death for: (i) all patients ("unselected" cohort), and on the basis of (ii) classic clinicopathologic features, (iii) clinical subtypes, (iv) PAM50-based molecular intrinsic subtypes, and (v) individual PAM50 target genes.
|
27488523 |
2016 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
To this end, we established a genetically engineered mouse model (GEMM) for BRCA1-deficient MBC by introducing the MET proto-oncogene into a BRCA1-associated breast cancer model, using our novel female GEMM ES cell (ESC) pipeline.
|
26100884 |
2015 |
|
Malignant neoplasm of breast
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
The HGF growth factor receptor MET is potentially functionally altered due to an uncommon germline single nucleotide polymorphism (SNP), MET-T1010I, in many cancer lineages including breast cancer where the MET-T1010I SNP is present in 2% of patients with metastatic breast cancer.
|
25605252 |
2015 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
SPSB1 may have MET its match during breast cancer recurrence.
|
25002612 |
2014 |
|
Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
High expression of MET in breast cancer resulted in poor overall survival (p = 0.001) and disease-free survival (DFS, p = 0.010).
|
24615768 |
2014 |
|
Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
This study identifies SPSB1 as a critical mediator of breast cancer recurrence, suggests activation of the SPSB1-c-MET pathway as an important mechanism of therapeutic resistance in breast cancers, and emphasizes that pharmacologic targets for recurrence may be unique to this stage of tumor progression.
|
24786206 |
2014 |
|
Malignant neoplasm of breast
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
A total of 107 patients with advanced BC were analyzed for MET mutation/variant (88 patients) or amplification (63 patients).
|
25065564 |
2014 |
|
Malignant neoplasm of breast
|
0.300 |
AlteredExpression
|
disease |
BEFREE |
These data show that a subset of ERBB2(+) breast cancers express MET and contain MET(+)/ERBB2(+) subpopulations.
|
23825050 |
2013 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
In conclusion, the results suggest that these genomic regions may contain important genes for this pathology, such as the oncogenes MET (7q31) and PIK3CA (3q26), and thus being interesting targets for future studies in breast cancer research.
|
23063927 |
2013 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Overall, our findings highlighted the effectiveness of c-MET inhibition in delaying the onset and progression of bone metastases and strongly suggest that targeting c-MET may have promising therapeutic value in the treatment of bone metastases from breast cancer.
|
22027690 |
2012 |